Genetic association studies have identified 210 risk loci for inflammatory bowel disease 1-7 , which 10 have revealed fundamental aspects of the molecular biology of the disease, including the roles of 11 autophagy and Th17 cell signaling and development. We performed a genome-wide association 12 study of 25,305 individuals, and meta-analyzed with published summary statistics, yielding a total 13 sample size of 59,957 subjects. We identified 26 new genome-wide significant loci, three of which 14 contain integrin genes that encode molecules in pathways identified as important therapeutic 15 targets in inflammatory bowel disease. The associated variants are also correlated with 16 expression changes in response to immune stimulus at two of these genes (ITGA4, ITGB8) and at 17 two previously implicated integrin loci (ITGAL, ICAM1). In all four cases, the stimulus-dependent 18 expression increasing allele also increases disease risk. We applied summary statistic fine-19 mapping and identified likely causal missense variants in the primary immune deficiency gene 20 PLCG2 and the negative regulator of inflammation, SLAMF8. Our results demonstrate that new 21 common variant associations continue to identify genes and pathways of relevance to therapeutic 22 target identification and prioritization.
2 response to treatment, or develop complications of IBD, with many ultimately requiring major abdominal 29 surgery. Previous genome-wide association studies (GWAS) and targeted follow-up using the 30 Immunochip have been very successful at identifying genetic risk loci for IBD, but increased biological 31 understanding has not yet had a significant impact on therapy for these disorders.
32
In order to further expand our understanding of the biology of these disorders we carried out a GWAS of 33 12,160 IBD cases and 13,145 population controls of European ancestry that had not been included in any 34 genome-wide meta-analysis of IBD to date (Supplementary Table  1 , Online Methods). We imputed 35 genotypes using a reference panel comprising whole genome sequences from 4,686 IBD cases 8 and 36 6,285 publically available population controls 9,10 . Following quality control (Online Methods) we tested 9.7 37 million sites for association. At the 232 IBD associated SNPs in the latest meta-analysis by the 38 International IBD Genetics Consortium 1 , 228 had effects in the same direction in our data, 188 showed at 39 least nominal evidence of replication (P<0.05) and none showed significant evidence of heterogeneity of 40 effect by Cochrane's Q test. Among these replicated loci was a genome-wide significant association on 41 chromosome 10q25 that was only previously significantly associated with Crohn's disease in individuals 42 of East Asian ancestry 3,7 , further supporting near complete sharing of genetic risk loci across 43 populations 1 . We meta-analyzed our new GWAS data with previously published summary statistics from 44 12,882 IBD cases and 21,770 population controls imputed using the 1000 Genomes Project reference 45 panel 1 ( Supplementary  Figures  1-3 , Supplementary  Table  2 ). We observed inflation of the summary 46 statistics (λ GC = 1.23 and 1.29 for Crohn's and ulcerative colitis, respectively), but LD score regression demonstrated that this was due to broad polygenic signal, rather than confounding population 48 substructure (both intercepts = 1.09, Online Methods).
49
We identified 26 new loci at genome-wide significance ( Table  1 ). In order to identify causal variants, 50 genes and mechanisms, we performed a summary-statistic fine-mapping analysis on these loci, as well 51 as 39 previously discovered loci where fine-mapping had not yet been attempted 11 (Online Methods, 52 Supplementary  Table  3 ). In order to be confident about fine-mapping inferences, we restricted 53 subsequent analyses to 12 signals where we had high quality imputed data for all relevant variants 54 (Online Methods) . At 6 of these 12 loci we identified a single variant with >50% probability of being causal 55 ( In addition to the connections to anti-integrin and anti-TGFβ therapies described above, IBD GWAS have 
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286
Testing for co-localization. We tested for co-localization between IBD association signals and eQTLs 287 using the coloc2 method 48 , implemented in the R package coloc. We used a window size of 250kb on repeated using two different values for the prior probability of co-localization, p 12 : 1x10 -5 and 1x10 -6 . −log10(P) 0 2 4 6 8 10 12
Extracellular Cytoplasmic −log10(P) 0 2 4 6 8 10 12 divided into the studies where they were first identified 1 Table  2 . Variants fine-mapped to >50% probability of being causal in their given locus.
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